Devon Krantz's guest appearances

Devon Krantz

CX Network

B2BiQ

Elie's Coffee Talks

Brian Mikkelsen

Anil Bhavnani

Timothy Renick

James Dodkins

Ravi Rao

Jack Cheng

Karen Tilstra

David Campos

Tyrone Grandison

Deborah Kops

Anshuman Das

Deepak Subbarao

Uzair Rashid

Rohit Amberker

Robert Welborn

OwlTail

Devon moved to Basel in January 2019 for work. She is the co-founder and managing director of Linum Labs, a Blockchain Start-Up. Originally from South Africa, she shares her perspectives about Switzerland and we also discuss: working remote / corporate life / presence based vs output based work systems/ the future of work / the challenges of being self-employed and being a female entrepreneur in a male dominated industry / mental-health / burn-out / failure and more!

#18 Devon Krantz

Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule’s CEO, Devon Krantz, discusses the dire state of pharmacological R&amp;D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: “We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP, and maybe it's in an underfunded area, and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We’re democratizing access to cures.” Devon elaborates on the innovative and complex ‘why &amp; how’ during the rest of the conversation.

<p>Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule’s CEO, Devon Krantz, discusses the dire state of pharmacological R&amp;D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: “We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP, and maybe it's in an underfunded area, and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We’re democratizing access to cures.” Devon elaborates on the innovative and complex ‘why &amp; how’ during the rest of the conversation.</p>

Ep. 141: Devon Krantz, Molecule

Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule’s CEO, Devon Krantz, discusses the dire state of pharmacological R&amp;D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: “We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We’re democratizing access to cures.” Devon elaborates on the innovative and complex ‘why &amp; how’ during the rest of the conversation.

<p>Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule’s CEO, Devon Krantz, discusses the dire state of pharmacological R&amp;D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: “We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We’re democratizing access to cures.” Devon elaborates on the innovative and complex ‘why &amp; how’ during the rest of the conversation.</p>

CX: Devon Krantz, Molecule